María
Díez Campelo
Publicacións (124) Publicacións de María Díez Campelo
2024
-
CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)
Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25
-
Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms
British Journal of Haematology
-
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes
Nature Communications, Vol. 15, Núm. 1
-
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, Vol. 403, Núm. 10423, pp. 249-260
-
Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation
JCO clinical cancer informatics, Vol. 8, pp. e2300205
-
Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells
Cytotherapy
-
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification
British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535
2023
-
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
The Lancet Haematology, Vol. 10, Núm. 2, pp. e117-e128
-
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
Blood
-
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice
Leukemia and Lymphoma, Vol. 64, Núm. 3, pp. 679-690
-
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
Annals of Hematology, Vol. 102, Núm. 2, pp. 311-321
-
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
Cancer Medicine, Vol. 12, Núm. 16, pp. 16788-16792
-
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
HemaSphere, Vol. 7, Núm. 10, pp. E961
-
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8
Cancers, Vol. 15, Núm. 15
-
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 15, pp. 2827-2842
-
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology
JCO clinical cancer informatics, Vol. 7, pp. e2300021
-
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution
eLife, Vol. 12
2022
-
Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells
Therapeutic Advances in Hematology, Vol. 13
-
Guiding the global evolution of cytogenetic testing for hematologic malignancies
Blood, Vol. 139, Núm. 15, pp. 2273-2284
-
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Leukemia, Vol. 36, Núm. 5, pp. 1432-1435